Our Research Methodology

We don't guess. We analyze using a rigorous, repeatable process that combines scientific scrutiny, financial modeling, and regulatory insight.

1. Scientific Due Diligence

We start with the biology. Our PhD/MD team evaluates the mechanism of action (MOA) to determine biological plausibility. We scrutinize preclinical data for clear signals of efficacy and safety, not just "promising" rhetoric.

• Detailed review of Mechanism of Action (MOA)
• Analysis of preclinical models and their relevance to human disease
• Evaluation of Phase 1/2 safety and efficacy signals

2. Clinical Trial Analysis

A good drug can fail in a bad trial. We analyze trial protocols (inclusion/exclusion criteria, endpoints, statistical power) to assess the probability of a positive readout.

• Trial design verification against FDA guidelines
• Statistical power analysis
• Competitor trial comparisons

3. Commercial & Valuation Assessment

Science alone isn't enough. We model the market opportunity, peak sales potential, and apply risk-adjusted NPV to determine if the stock is undervalued relative to its potential.

• Total Addressable Market (TAM) modeling
• Competitive landscape analysis
• Risk-adjusted Net Present Value (rNPV) calc